Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas |
| |
| Authors: | Adam Levin MD Nirav N Shah |
| |
| Institution: | Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin |
| |
| Abstract: | Chimeric antigen receptor modified T (CAR-T) cell therapy against the CD19 antigen has revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non-Hodgkin lymphoma (NHL). Currently, there are two FDA approved products (axicabtagene ciloleucel and tisagenlecleucel) for B cell NHL, with several other constructs under clinical investigation. This review will focus on the clinical outcomes, toxicity profile, and differences among candidate CD19 CAR-T cell products for major subtypes of B cell NHL including diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Lastly, we will describe novel CAR-T constructs currently under exploration in B cell NHL. |
| |
| Keywords: | |
|
|
